Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus Venetoclax in Front Line Marginal Zone Lymphoma
NCT06510309Phase 2Recruiting
- Start
- Feb 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in marginal zone lymphoma (MZL). Started Feb 2026; status: recruiting.
02
Drugs
venetoclax
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06510309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510309.